Mevalonate Pathway Dynamics in Cancer Biology

The mevalonate pathway is a central biosynthetic route that converts acetyl-CoA into cholesterol and nonsterol isoprenoids, supporting membrane architecture, protein prenylation and intracellular signalling. Dysregulation of this pathway is a hallmark of many malignancies, where elevated flux drives proliferation, metastasis and the maintenance of cancer stem cell populations. Cancer cells often upregulate 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme, and sterol regulatory element-binding protein 2 (SREBP2) to replenish intracellular sterols. Feedback loops triggered by statin drugs lead to compensatory enzyme induction, resulting in resistance. Mevalonate-derived intermediates contribute to oncogenic pathways, including small GTPase activation, YAP1 nuclear localisation and Hedgehog signalling, while high cholesterol levels modulate immune evasion via the cGAS–STING axis. Therapeutic targeting of this metabolic node utilises statins, bisphosphonates and novel inhibitors of pathway transcriptional regulators, alongside combination strategies with kinase inhibitors or immune modulators. Recent advances highlight the influence of diet and tumour microenvironment on mevalonate pathway dynamics, underscoring its global significance in cancer biology and therapy.

Research from Nature Portfolio

A foundational study has demonstrated that the dietary intake of geranylgeraniol, a mevalonate pathway intermediate, can negate the antitumour efficacy of a lipophilic statin in ovarian cancer models. This work revealed that geranylgeraniol supplementation restores mevalonate-derived prenylation and cell survival despite HMGCR inhibition, emphasising the need to control dietary precursors in clinical interventions. The findings also underscored the importance of statin pharmacokinetics, suggesting that long half-life agents combined with dietary regulation may improve therapeutic responses in statin-refractory ovarian tumours.

Mevalonate Pathway Dynamics in Cancer Biology publication trend

The graph below shows the total number of articles in mevalonate pathway dynamics in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Mevalonate pathway: A metabolic cascade converting acetyl-CoA to cholesterol and isoprenoid intermediates.

HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase): The rate-limiting enzyme controlling mevalonate synthesis.

SREBP2 (sterol regulatory element-binding protein 2): A transcription factor that upregulates genes for cholesterol biosynthesis under low-sterol conditions.

Protein prenylation: Post-translational lipid modification of proteins, essential for membrane localisation and small GTPase signalling.

References

1. Cholesterol biosynthesis induced by radiotherapy inhibits cGAS–STING activation and contributes to colorectal cancer treatment resistance. Experimental & Molecular Medicine (2025).
2. CSN6‐SPOP‐HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation. Advanced Science (2024).
3. Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma. Cancer Research (2023).
4. Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation. Biomedicine & Pharmacotherapy (2024).
5. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death & Disease (2019).
6. Inhibiting HMGCR represses stemness and metastasis of hepatocellular carcinoma via Hedgehog signaling. Genes & Diseases (2024).
7. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Scientific Reports (2017).